Cancer-associated thrombosis: prevention and treatment
2008

Cancer-Associated Thrombosis: Prevention and Treatment

Sample size: 2373 publication Evidence: moderate

Author Information

Author(s): Brose K.M.J., Lee A.Y.Y.

Primary Institution: Queen’s University, Kingston, Ontario; Department of Medicine, McMaster University, Hamilton, Ontario

Hypothesis

What are the optimal methods for preventing and treating venous thromboembolism in cancer patients?

Conclusion

Cancer patients are at high risk for venous thromboembolism and require effective prophylaxis and treatment strategies.

Supporting Evidence

  • Cancer patients have a 4 to 6 times higher risk of venous thromboembolism.
  • 15%–20% of patients diagnosed with venous thromboembolism have cancer.
  • Patients with cancer receiving warfarin experience significantly more major bleeding episodes.
  • Primary prevention is the most effective way to reduce morbidity and mortality from cancer-associated thrombosis.
  • Extended prophylaxis can reduce the risk of venous thromboembolism by 60%.

Takeaway

Cancer patients can get blood clots more easily, so doctors need to help prevent this with medicine and other methods.

Methodology

The study reviews recent evidence on the prevention and treatment of venous thromboembolism in cancer patients, including randomized controlled trials.

Potential Biases

Potential bias due to underutilization of established guidelines by physicians.

Limitations

Limited data on the effectiveness of prophylaxis in outpatient settings and the lack of studies specifically targeting hospitalized cancer patients.

Participant Demographics

Cancer patients undergoing various treatments and surgeries.

Statistical Information

P-Value

0.002

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication